Table 3.

Characteristics of patients treated with PI3K/AKT/mTOR inhibitors according to the presence of H1047R mutation

VariableH1047R mutation (%)Other PIK3CA mutations (%)P
Number16 (100)50 (100)
Median of prior therapies, range3, 1–123, 1–100.67
Colorectal cancer2 (13)15 (30)0.20
Ovarian cancer4 (25)6 (12)0.24
Breast cancer5 (31)7 (14)0.14
Endometrial cancer3 (19)6 (12)0.68
Head and neck squamous cell cancer1 (6)3 (6)1.00
Small intestine cancer1 (6)0 (0)0.24
Cervical squamous cell cancer0 (0)6 (12)0.32
Renal cell cancer0 (0)2 (4)1.00
Other cancers0 (0)5 (10)0.32
Treatment with PI3K/AKT/mTOR inhibitor-based combinations12 (75)26 (52)0.15
Treatment with rapalogs14 (88)38 (76)0.49